NRX PHARMACEUTICALS INC

The latest price of NRXP is displayed at the top of this stock detail page and updates with market activity. Because share prices change throughout the trading day, any figure quoted here could be stale by the time you read it. For an accurate, real-time quote, including the day's open, high, low, and volume, please refer to the live data shown on this page.

NRXP has historically shown significant price volatility, which is common for small-cap biopharmaceutical companies whose fortunes can hinge on clinical trial outcomes, regulatory decisions, and financing news. Daily percentage moves may be larger than those of diversified large-cap stocks. Investors can review NRXP's beta, average true range, and recent daily price swings on this page to gauge current volatility levels.

Valuation for a clinical-stage biopharma like NRXP often relies on more than traditional earnings multiples, since the company may not yet be consistently profitable. Investors commonly examine price-to-book, enterprise value, cash position, and pipeline progress. Because NRXP's fundamentals and share count can change, review the latest valuation metrics and financial statements displayed on this page rather than relying on static figures.

NRXP trades on a major U.S. exchange and can be purchased through a brokerage account that offers U.S. equities. You would search for the ticker NRXP, enter a market or limit order, and specify the number of shares. Availability of fractional shares, commissions, and order types varies by broker. Check your brokerage platform for its specific trading rules before placing an order.

NRXP does not currently pay a dividend. The company is a clinical-stage biopharmaceutical firm that generally reinvests available capital into research, development, and clinical programs rather than returning cash to shareholders. For the most current dividend status, including any future policy changes, refer to the dividend information section on this NRXP page.

Key risks for NRXP include clinical trial failures, regulatory setbacks, reliance on a limited pipeline, potential need for additional capital that could dilute shareholders, and competition from larger pharmaceutical companies. As a small-cap stock, NRXP may also experience lower liquidity and sharper price swings. Investors should review the risk factors disclosed in NRXP's SEC filings and the financial data on this page.